Group 1 - The core viewpoint of the article highlights an unprecedented wave of IPO applications from over 13 medical device companies in China, marking a significant shift in the industry as multiple sectors prepare to launch their "first stocks" [2][3][4] - The medical device market in China is projected to reach 1.22 trillion yuan by 2025, reflecting a growth of approximately 30% from 941.7 billion yuan in 2024, indicating a robust market outlook [4][15] - The reactivation of the fifth listing standard on the STAR Market has lowered the barriers for high R&D investment companies, facilitating the entry of innovative firms that may not yet be profitable [3][15][20] Group 2 - The competition for the title of "first stock" in various segments is intensifying, with companies like Core Medical and Tongxin Medical vying for leadership in the artificial heart market [5][17] - Notable companies such as Jinjiang Electronics and Saiwei Technology are also advancing their IPO processes, with Jinjiang Electronics having launched China's first domestic cardiac mapping system [6][18] - The financing landscape is shifting, with total financing in the first half of 2025 increasing by 17.01% year-on-year to 16.695 billion yuan, indicating a trend towards concentrated investment in validated innovative enterprises [4][16] Group 3 - Despite the promising outlook, many innovative medical device companies face significant profitability challenges due to high R&D costs and long development cycles, with Core Medical reporting R&D expenditures of 119 million yuan, 151 million yuan, and 87.5 million yuan from 2023 to mid-2025 [8][20] - Companies are adjusting their pricing strategies to penetrate the market, with Core Medical's average sales price for its commercialized product dropping from 290,400 yuan in 2023 to 229,600 yuan in the first half of 2025 [9][21] - The IPO process is seen as a critical pathway for these companies to secure low-cost funding, advance clinical research, and expand production capabilities [9][22]